Did you know?

Exact Sciences Corporation (EXAS 0.10%) became one of the best-performing stocks of 2017.A successful marketing blitz helped test volumes soar, and they're still climbing. Now that Cologuard's ...Provides Access to Industry-Leading Sequencing Lab and Plans for 10-Year Partnership with National Cancer Research Leaders Exact Sciences Corp. (Nasdaq: EXAS) today announced that it has entered into an agreement to acquire Ashion Analytics, LLC (Ashion) from The Translational Genomics Research Institute (TGen), an affiliate of … Corporate Impact and Community Relations. 0:59. At Exact Sciences, we support the health of our communities, wellbeing of our employees and take responsibility to make positive change for our environment. To us, community isn’t defined solely by geographic lines. It’s a feeling and identity shared by those connected through common ... Exact Sciences Corporation charges healthcare providers for these laboratory services, which include the costs associated with the processing, analysis, and reporting of each Cologuard test. This revenue stream is essential to the company's financial model, as it provides a recurring source of income from the ongoing demand for …2022 Annual Meeting of Shareholders of Exact Sciences Corporation. When. 10:00 A.M. CT on Thursday, June 9, 2022. Where.Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $553.0 million for the fourth quarter of 2022 and $2,084.3 million for the full year of 2022, both ended Dec. 31, 2022.Exact Sciences Corp. (Nasdaq: EXAS) today announced that it has completed its previously announced acquisition of Thrive Earlier Detection Corp. ("Thrive"). "Bringing Thrive into the Exact Sciences family marks a giant leap toward blood-based, multi-cancer screening becoming a reality and eventually the standard of care," said Kevin Conroy, chairman and CEO of Exact Sciences.Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $523 million for the third quarter ended September 30, 2022, compared to $456 million for the same period of 2021. "Exact Sciences third quarter results demonstrate the strength …Exact Sciences Corporation 5505 Endeavor Lane, Madison, WI 53719 To report suspected Adverse Events or product problems, please contact the Exact Sciences Laboratories Customer Care Center at 1-844-870-8870 .Have you ever wondered about the history of your home? Maybe you’re curious to know when it was built and who lived there before you. Uncovering the exact date your house was built...Sep 10, 2022 · MADISON, Wis., September 10, 2022 -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced data from a multi-cancer early detection (MCED) biomarker validation study was presented at the European Society for Medical Oncology (ESMO) Congress. The study rigorously assessed the ... View the latest Exact Sciences Corp. (EXAS) stock price, news, historical charts, analyst ratings and financial information from WSJ. Sep 10, 2022 · MADISON, Wis., September 10, 2022 -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced data from a multi-cancer early detection (MCED) biomarker validation study was presented at the European Society for Medical Oncology (ESMO) Congress. The study rigorously assessed the ... MADISON, Wis. and CAMBRIDGE, Mass., Oct. 27, 2020 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) and Thrive Earlier Detection Corp. ("Thrive"), a healthcare company dedicated to incorporating earlier cancer detection into routine medical care, today announced they have entered into a definitive agreement under which Exact …MADISON, Wis., February 28, 2024--Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, today announced the launch of the Riskguard™ hereditary cancer test in the ...Exact Sciences Announces Preliminary Fourth Quarter 2021 Results. January 9, 2022. - Expected total fourth quarter revenue of $472-475M, including Screening revenue of $277-278M, Precision Oncology revenue of $148.5-149.5M, and COVID-19 testing revenue of $46.5-47.5M. - Total 2021 revenue, excluding COVID-19 testing, increased 29% …There's been a notable change in appetite for Exact Sciences Corporation (NASDAQ:EXAS) shares in the week since its quarterly report, with the stock down 14% to US$53.51. Revenues were in line ...So, what exactly is just one corporate client worth to your small business? The more you think about it, the more you begin to realize it could be more than you imagined. So, what ...Exact Sciences to Present Late-Breaking Data from ASCEND-2 Study Validating Its Investigational Multi-Cancer Early Detection Test at AACR Annual Meeting 2024. April 05, 2024.Exact Sciences’ products, services, mission, and people all work together to support early cancer detection and smarter treatment decisions.Exact Sciences is founded. February 2001. Initial Public Offering. April 2009. Kevin Conroy becomes President and Chief Executive Officer. August 2009. Graham Lidgard, PhD is …Exact Sciences 2023 Investor Day. June 21, 2023 11:00 AM ET. Exact Sciences 2023 Investor Day Transcript. Exact Sciences 2023 Investor Day Presentation.Exact Sciences Corporation isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Thank you …

EXACT Sciences Corp. is a molecular diagnostics company, which focuses on the early detection and prevention of colorectal cancer. It developed Cologuard,Exact Sciences. Address: 445 N. 5th Street Phoenix, AZ 85004 Phone: (602) 850-7000Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non …MADISON, Wis., Feb. 22, 2022 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS ), a leader in advanced cancer diagnostics, today announced that the company generated revenue of $473 .8 million ...Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the launch of the OncoExTra™ therapy selection test in the United States. OncoExTra is a next-generation sequencing (NGS), comprehensive DNA and RNA based genomic test providing doctors and their patients a complete molecular ...

About EXAS. Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.Have you ever wondered about the history of your home? Maybe you’re curious to know when it was built and who lived there before you. Uncovering the exact date your house was built...EXAS. There's been a notable change in appetite for Exact Sciences Corporation ( NASDAQ:EXAS) shares in the week since its quarterly report, with the ……

Reader Q&A - also see RECOMMENDED ARTICLES & FAQs. BLUE-C study met all endpoints, showing improve. Possible cause: Latest Quarterly Results · Conference Call · Earnings Pres.